A Menter

Summary

Publications

  1. ncbi request reprint The status of biologic therapies in the treatment of moderate to severe psoriasis
    Alan Menter
    Psoriasis Research Unit, Baylor Research Institute, Dallas, Texas, USA
    Cutis 84:14-24. 2009
  2. ncbi request reprint Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Psoriasis Research Center, Baylor Research Institute, Baylor University Medical Center, 3900 Junius St, Ste 145, Dallas, TX 75246, USA
    Cutis 89:89-94. 2012
  3. ncbi request reprint Emerging topical treatments for psoriasis
    Dario N Kivelevitch
    Baylor University Medical Center, Department of Dermatology, 3900 Junius Street, Suite 125, Dallas, TX 75246, USA 1972 354 7988 1 972 715 1460
    Expert Opin Emerg Drugs 18:523-32. 2013
  4. ncbi request reprint Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial
    Alan Menter
    Dermatology Department, Baylor University Medical Center, Dallas, TX, USA
    J Drugs Dermatol 12:92-8. 2013
  5. pmc Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland, USA
    Health Qual Life Outcomes 6:75. 2008
  6. doi request reprint The ethics of consulting with pharmaceutical companies
    Andrew Miner
    The University of Texas Southwestern, Dallas, TX, USA
    Clin Dermatol 27:339-45. 2009
  7. ncbi request reprint Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations
    Alan Menter
    Psoriasis Research Unit, Baylor Research Institute, Dallas, TX, USA
    J Drugs Dermatol 7:1137-46. 2008
  8. ncbi request reprint Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Research Institute, Dallas, TX, USA
    J Drugs Dermatol 8:52-7. 2009
  9. doi request reprint The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial
    Alan Menter
    Baylor Psoriasis Research Institute, Dallas, TX, USA
    J Am Acad Dermatol 62:812-8. 2010
  10. ncbi request reprint Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    Alan Menter
    Division of Dermatology, Baylor Research Institute, University of Texas Southwestern Medical School, 3900 Junius St, 125, Dallas, TX 75246 1613, USA
    J Am Acad Dermatol 58:106-15. 2008

Detail Information

Publications98

  1. ncbi request reprint The status of biologic therapies in the treatment of moderate to severe psoriasis
    Alan Menter
    Psoriasis Research Unit, Baylor Research Institute, Dallas, Texas, USA
    Cutis 84:14-24. 2009
    ..Prospective trials of this sort are therefore needed to better understand the potential risks and benefits of such approaches...
  2. ncbi request reprint Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Psoriasis Research Center, Baylor Research Institute, Baylor University Medical Center, 3900 Junius St, Ste 145, Dallas, TX 75246, USA
    Cutis 89:89-94. 2012
    ..05%. Clobetasol propionate spray 0.05% is a topical product with a documented efficacy and safety profile with good acceptability in patients with moderate to severe plaque psoriasis...
  3. ncbi request reprint Emerging topical treatments for psoriasis
    Dario N Kivelevitch
    Baylor University Medical Center, Department of Dermatology, 3900 Junius Street, Suite 125, Dallas, TX 75246, USA 1972 354 7988 1 972 715 1460
    Expert Opin Emerg Drugs 18:523-32. 2013
    ..Approximately 80% of patients have a mild-to-moderate form routinely treated with topical medications, whereas phototherapy, systemic and biological therapies are typically reserved for treatment of moderate-to-severe psoriasis...
  4. ncbi request reprint Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial
    Alan Menter
    Dermatology Department, Baylor University Medical Center, Dallas, TX, USA
    J Drugs Dermatol 12:92-8. 2013
    ....
  5. pmc Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland, USA
    Health Qual Life Outcomes 6:75. 2008
    ..To evaluate the impact of adalimumab on health-related quality of life (HRQOL) for patients with moderate to severe plaque psoriasis...
  6. doi request reprint The ethics of consulting with pharmaceutical companies
    Andrew Miner
    The University of Texas Southwestern, Dallas, TX, USA
    Clin Dermatol 27:339-45. 2009
    ..These include publication and prescribing bias. These also lead to the real or apparent conflict of interest when the consultant receives unearned, unjustified, or excessive compensation and gifts...
  7. ncbi request reprint Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations
    Alan Menter
    Psoriasis Research Unit, Baylor Research Institute, Dallas, TX, USA
    J Drugs Dermatol 7:1137-46. 2008
    ..Infliximab is indicated for severe plaque psoriasis (PsO). The investigators compared safety event rates in infliximab PsO trials with those of the general United States and PsO populations...
  8. ncbi request reprint Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Research Institute, Dallas, TX, USA
    J Drugs Dermatol 8:52-7. 2009
    ..003). Adverse events were reported by less than one-third of patients from each treatment group (31% for CP spray and 33% for C-BD ointment)...
  9. doi request reprint The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial
    Alan Menter
    Baylor Psoriasis Research Institute, Dallas, TX, USA
    J Am Acad Dermatol 62:812-8. 2010
    ..Psoriasis is associated with health-related quality-of-life impairment and depression...
  10. ncbi request reprint Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    Alan Menter
    Division of Dermatology, Baylor Research Institute, University of Texas Southwestern Medical School, 3900 Junius St, 125, Dallas, TX 75246 1613, USA
    J Am Acad Dermatol 58:106-15. 2008
    ..Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis...
  11. ncbi request reprint A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
    Alan Menter
    Division of Dermatology, Baylor University Medical Center, UT Southwestern Medical School, 5310 Harvest Hill Rd, Ste 260, Dallas, TX 75230, USA
    J Am Acad Dermatol 56:31.e1-15. 2007
    ..Previous studies of infliximab in psoriasis have demonstrated rapid improvement with induction therapy and sustained response with regularly administered maintenance therapy...
  12. ncbi request reprint The science and art of dermal fillers for soft-tissue augmentation
    Jean Carruthers
    Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, Canada
    J Drugs Dermatol 8:335-50. 2009
    ....
  13. doi request reprint Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
    Alan Menter
    Baylor Psoriasis Research Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    J Am Acad Dermatol 63:448-56. 2010
    ....
  14. ncbi request reprint One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses
    Alan Menter
    Baylor University Medical Center, Division of Dermatology, Dallas, TX 75246, USA
    Cutis 81:509-16. 2008
    ..Using this short treatment duration period in combination with cryosurgery may prove beneficial in clinical practice. Extending treatment for up to 4 weeks will further improve AK lesion clearance rates...
  15. ncbi request reprint Psoriasis: comorbidities and associations
    E Farley
    Department of Dermatology, Baylor University Medical Center, Dallas, TX 75246, USA
    G Ital Dermatol Venereol 146:9-15. 2011
    ..Within this article we will discuss the associations between psoriasis and multiple systemic health problems...
  16. ncbi request reprint Psoriasis and cardiovascular disorders
    C Ryan
    Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA
    G Ital Dermatol Venereol 147:179-87. 2012
    ..In this article we review the association of psoriasis with cardiovascular disorders and the effects of current psoriasis therapies on cardiovascular risk...
  17. ncbi request reprint Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial
    Alan Menter
    Baylor Psoriasis Research Center, Baylor Research Institute, Dallas, Texas, USA
    Cutis 80:12-9. 2007
    ..Based on these data, clobetasol propionate spray 0.05% is an effective and convenient topical monotherapy for moderate to severe plaque psoriasis...
  18. ncbi request reprint Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Drugs Dermatol 6:428-35. 2007
    ..Calcitriol 3 microg/g ointment has demonstrated good clinical efficacy as well as topical and systemic safety when used to treat psoriasis...
  19. doi request reprint Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians
    A Perlmutter
    Baylor Research Institute, 3900 Junius Street, Suite 145, Dallas, TX 75246, USA
    Br J Dermatol 160:8-15. 2009
    ....
  20. ncbi request reprint Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, TX, USA
    Arch Dermatol 141:31-8. 2005
    ..To assess the efficacy and safety of a 24-week course of efalizumab...
  21. ncbi request reprint Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy
    Qurat Ul Ain Kamili
    Baylor Research Institute, Dallas, TX 75246, USA
    J Drugs Dermatol 9:57-60. 2010
    ..In addition, the authors emphasize the role of a multi-disciplinary approach and appropriate coordination among caregivers...
  22. ncbi request reprint Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade
    Laura Winterfield
    Department of Dermatology, University of Texas Southwestern Medical School, Dallas, TX, USA
    Dermatol Clin 22:437-47, ix. 2004
    ..Comprehensive evaluation in controlled trials may allow infliximab to take its place among the expanding group of biologic drugs for the treatment of moderate to severe psoriasis...
  23. pmc Psoriasis treatment: current and emerging directed therapies
    L S Winterfield
    Department of Dermatology, University of Texas Southwestern Medical School, Dallas, Texas 75230, USA
    Ann Rheum Dis 64:ii87-90; discussion ii91-2. 2005
    ..Close cooperation between dermatologists and rheumatologists, particularly in the area of psoriatic joint disease, will enhance these considerations...
  24. ncbi request reprint The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey
    G Krueger
    Department of Dermatology, University of Utah Medical School, 50 N Medical Dr, Salt Lake City, UT 84132, USA
    Arch Dermatol 137:280-4. 2001
    ..Physicians may need to improve communication with their patients and should reevaluate their management of psoriasis...
  25. ncbi request reprint Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study
    Carin Gribetz
    Mt Sinai School of Medicine, Department of Dermatology, New York, New York, USA
    J Am Acad Dermatol 51:731-8. 2004
    ..Pimecrolimus, a well-tolerated, nonatrophogenic, skin-selective inflammatory cytokine inhibitor, has been shown to be effective in the treatment of psoriasis when applied topically under occlusion...
  26. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 61:451-85. 2009
    ..We will also briefly discuss the available data for the use of azathioprine, fumaric acid esters, hydroxyurea, leflunomide, mycophenolate mofetil, sulfasalazine, tacrolimus, and 6-thioguanine in psoriasis...
  27. doi request reprint Topical treatment of psoriasis
    Qurat Ul Ain Kamili
    Psoriasis Research Unit, Baylor Research Institute, Dallas, Texas, USA
    Curr Probl Dermatol 38:37-58. 2009
    ..This will help alleviate the common problem of poor patient adherence, and inevitably result in more optimal clinical outcomes...
  28. ncbi request reprint Verrucous linear (segmental) psoriasis of the right leg responding to radiation therapy
    Fiona Larsen
    Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, TX 75390 9023, USA
    J Drugs Dermatol 7:969-71. 2008
    ..The hypertrophic nature of the plaques makes treatment particularly challenging. The authors present a case of verrucous linear psoriasis of the right leg that responded to radiation therapy...
  29. ncbi request reprint Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    Int J Dermatol 46:637-48. 2007
    ..To prevent rebound on discontinuation of efalizumab, this study evaluated the effectiveness of transitioning patients to an alternative psoriasis therapy...
  30. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
    ..We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis...
  31. ncbi request reprint Ciclopirox gel in the treatment of patients with interdigital tinea pedis
    Raza Aly
    Department of Dermatology, University of California San Francisco, USA
    Int J Dermatol 42:29-35. 2003
    ..Ciclopirox, a broad-spectrum hydroxypyridone antifungal, has proven efficacy against the organisms commonly implicated in tinea pedis; Trichophyton rubrum, T.mentagrophytes and Epidermophyton floccosum...
  32. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 58:826-50. 2008
    ..Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis...
  33. ncbi request reprint Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Medical Center, Dallas, Texas, USA
    J Drugs Dermatol 3:27-38. 2004
    ....
  34. ncbi request reprint Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
    B Strober
    Department of Dermatology, University of Connecticut School of Medicine, Farmington, CT, 06032, U S A Probity Medical Research, Waterloo, ON, Canada
    Br J Dermatol 169:992-9. 2013
    ..The Janus kinase (JAK) inhibitor, tofacitinib, has shown efficacy for the treatment of psoriasis in a phase IIb trial (A3921047; NCT00678210)...
  35. ncbi request reprint Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis
    S R Feldman
    Department of Dermatology, Wake Forest University, School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Br J Dermatol 150:317-26. 2004
    ..Psoriasis has a negative impact on patients' quality of life. Treatment strategies should address both the cutaneous manifestations of the disease and their impact on quality of life...
  36. ncbi request reprint Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis
    M Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York University 10029-6574, USA
    J Am Acad Dermatol 45:544-53. 2001
    ....
  37. ncbi request reprint Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study
    A Shalita
    Department of Dermatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203 2098, USA
    J Drugs Dermatol 4:153-8. 2005
    ..Tazarotene cream offers significantly greater efficacy and comparable tolerability to adapalene cream...
  38. ncbi request reprint Cyclosporine and tacrolimus in dermatology
    J C Cather
    Texas Dermatology Associates, Baylor Medical Center, Dallas, Texas, USA
    Dermatol Clin 19:119-37, ix. 2001
    ..This article reviews two such agents, cyclosporine and tacrolimus. Discussion emphasizes the pharmacology, side effects, and uses of these two drugs in dermatologic disorders...
  39. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 60:643-59. 2009
    ....
  40. ncbi request reprint Combining traditional agents and biologics for the treatment of psoriasis
    Jennifer Clay Cather
    Baylor University Medical Center, Dallas, TX, USA
    Semin Cutan Med Surg 24:37-45. 2005
    ..A review of the literature, plus our personal experience in using combinations of traditional agents and biologics, is presented...
  41. ncbi request reprint Current and future management of psoriasis
    Alan Menter
    Baylor Research Institute and Southwestern Medical School, Dallas, Texas 75246, USA
    Lancet 370:272-84. 2007
    ..Other innovative treatments are undergoing clinical studies, with the aim of maintaining safe, long-term control of the condition...
  42. ncbi request reprint Case studies in severe psoriasis: A clinical strategy
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Box 1047, New York, NY 10029 6574, USA
    J Dermatolog Treat 14:26-46. 2003
    ..The purpose of the algorithms is to make optimum use of phototherapy, traditional cytotoxic and immunosuppressive agents, retinoids, and newer biologic agents...
  43. ncbi request reprint Ciclopirox gel for seborrheic dermatitis of the scalp
    Raza Aly
    Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
    Int J Dermatol 42:19-22. 2003
    ..Typically, sites dense with sebaceous glands support growth of the lipophilic yeast Malassezia furfur. Ciclopirox (Loprox) gel is a hydroxypyridone, broad-spectrum antifungal agent proven effective against the yeast M. furfur...
  44. doi request reprint Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community
    A Menter
    Psoriasis Research Unit, Baylor Research Unit, Dallas, TX, USA
    J Eur Acad Dermatol Venereol 24:1371-7. 2010
    ..Second, the design and implementation of lifestyle modification plans including exercise, diet and the limitation of alcohol and tobacco intake, will not only benefit their general medical health but also their psoriasis...
  45. ncbi request reprint A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
    Christopher S Carlin
    Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA
    J Am Acad Dermatol 50:859-66. 2004
    ..We conclude that PASI 50 equates to a clinically meaningful improvement in psoriasis and represents a discerning primary endpoint...
  46. ncbi request reprint Rationale for the use of topical corticosteroids in melasma
    Alan Menter
    Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA
    J Drugs Dermatol 3:169-74. 2004
    ..01% suppresses biosynthetic and secretory functions of melanocytes, and thus melanin production, leading to early response in melasma, synergy among the three agents, and no significant side effects over an 8-week period...
  47. ncbi request reprint Infliximab
    Laura S Winterfield
    Department of Dermatology, University of Texas Southwestern Medical School, Dallas, Texas, USA
    Dermatol Ther 17:409-26. 2004
    ..Practical issues such as patient selection, monitoring, cost, and potential combination therapies are also discussed...
  48. doi request reprint The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis
    Caitriona Ryan
    Department of Dermatology, Baylor Research Institute, Dallas, Texas, USA
    Mol Diagn Ther 14:81-93. 2010
    ....
  49. ncbi request reprint Practical considerations in future psoriasis therapies
    Christy Riddle
    Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Dermatol Clin 22:487-92, x. 2004
    ..Several tiers of psoriasis care are outlined to encourage individual physicians to choose the optimum level of service compatible with their individual practices...
  50. ncbi request reprint Combination therapy to treat moderate to severe psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, Mt Sinai Medical Center, 5 E 98th Street, 12th Floor, New York, NY 10029 6574, USA
    J Am Acad Dermatol 50:416-30. 2004
    ....
  51. ncbi request reprint The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy
    Alan Menter
    Baylor University Medical Center, Texas Dermatology Associates, 5310 Harvest Hill Road, Suite 260, Dallas, TX 75230, USA
    J Cutan Med Surg 8:20-5. 2004
    ..Alefacept helps fulfill the needs of psoriasis patients by providing efficacy, safety, off-treatment remissions, and improvement in QOL...
  52. ncbi request reprint Long-term management of plaque psoriasis with continuous efalizumab therapy
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:S182-8. 2006
  53. ncbi request reprint The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:61-3. 2006
    ..30 [1.26-4.19]). Alefacept provided incremental efficacy over 5 successive 12-week treatment courses...
  54. ncbi request reprint Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes
    Leon Kircik
    Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA
    J Drugs Dermatol 7:245-53. 2008
    ..Etanercept and narrow-band ultraviolet light B (NB-UVB) are widely used to treat this disease...
  55. ncbi request reprint Efalizumab: continuous therapy for chronic psoriasis
    Jennifer Clay Cather
    Baylor University Medical Center, 5310 Harvest Hill Rd, Ste 260, Dallas, TX75230, USA
    Expert Opin Biol Ther 5:393-403. 2005
    ..Efalizumab may thus potentially offer patients a safe option for long-term safe control in managing their disease...
  56. ncbi request reprint Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis
    Amy Perlmutter
    Baylor Research Institute, Dallas, Texas 75246, USA
    J Am Acad Dermatol 58:116-24. 2008
    ..A proportion of patients responding to therapy have been reported to experience remissions of approximately 7 to 8 months, characterized by disease-free and treatment-free intervals...
  57. ncbi request reprint Psoriasis as the marker of underlying systemic disease
    A S Kourosh
    The University of Texas Southwestern Medical School, Dallas, TX, USA
    Skin Therapy Lett 13:1-5. 2008
    ....
  58. doi request reprint Psoriasis: improving adherence to topical therapy
    Steven R Feldman
    Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    J Am Acad Dermatol 59:1009-16. 2008
    ..By understanding and manipulating the factors that affect treatment adherence, improvement in adherence is possible and hence better control and outcomes in the topical treatment of psoriasis are likely...
  59. ncbi request reprint Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab
    Jennifer Clay Cather
    Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA
    Expert Opin Biol Ther 3:361-70. 2003
    ....
  60. doi request reprint The use of cyclosporine in dermatology: part II
    Caitriona Ryan
    Department of Dermatology at Baylor University Medical Center, Dallas, Texas 75246, USA
    J Am Acad Dermatol 63:949-72; quiz 973-4. 2010
    ..The use of cyclosporine in pregnancy and in the pediatric population is also addressed...
  61. ncbi request reprint PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema
    William Abramovits
    Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Skinmed 4:275-81. 2005
    ..The authors have observed significant overlap between these two conditions such that a distinction between them may not always be made, even with histologic examination of skin biopsy specimens...
  62. doi request reprint Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool
    Elizabeth Farley
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 60:1024-31. 2009
    ..Palmoplantar psoriasis is associated with significant quality-of-life issues. Its epidemiology and phenotypical expression remain ill defined...
  63. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy
    Alan Menter
    Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 62:114-35. 2010
    ..Finally, where available, we will summarize the available data that compare the safety and efficacy of the different forms of UV light therapy...
  64. ncbi request reprint Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts
    Kenneth B Gordon
    Department of Medicine, Division of Dermatology, Loyola University Medical Center, Maywood, IL 60153, USA
    Arch Dermatol 139:1563-70. 2003
    ..To examine the relationship between the pharmacodynamic and antipsoriatic effects of alefacept, a biologic agent that targets CD4+ and CD8+ memory T cells...
  65. ncbi request reprint Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne
    John J DiGiovanna
    Division of Dermatopharmacology, Department of Dermatology, Brown Medical School Rhode Island Hospital, Providence, RI 02903, USA
    J Am Acad Dermatol 51:709-17. 2004
    ..The effect of short-term (4-5 months) therapy at the lower dose recommended for acne on bone development in younger, growing adolescent (12-17 years) patients has not been well studied...
  66. ncbi request reprint Decision points for the initiation of systemic treatment for psoriasis
    Steven R Feldman
    Department of Dermatology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1071, USA
    J Am Acad Dermatol 53:101-7. 2005
    ....
  67. doi request reprint A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach
    Bruce Strober
    Department of Dermatology, New York University Medical Center, New York, NY, USA
    J Am Acad Dermatol 61:S1-S46. 2009
    ..The final rankings and analysis provide guidance for practical, safe, and efficacious treatment options in a number of complex psoriasis scenarios...
  68. doi request reprint Comorbidities in psoriasis patients
    Noori Kim
    University of Texas Southwestern, Dallas, TX
    Semin Cutan Med Surg 29:10-5. 2010
    ..Psoriasis, with its comorbidities, must be approached in a multidisciplinary manner to effectively and comprehensively understand, manage, and treat those with this complex disorder...
  69. pmc Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways
    Rajan P Nair
    Department of Dermatology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Nat Genet 41:199-204. 2009
    ..Our results expand the catalog of genetic loci implicated in psoriasis susceptibility and suggest priority targets for study in other auto-immune disorders...
  70. ncbi request reprint Novel therapies for psoriasis
    Jennifer Cather
    Baylor University Medical Center, Dallas, Texas, USA
    Am J Clin Dermatol 3:159-73. 2002
    ..For the 2 to 3% of the worldwide population of patients with psoriasis the future has never looked brighter...
  71. ncbi request reprint Changing paradigms in dermatology: nuclear hormone receptors
    Laura Winterfield
    Department of Dermatology University of Texas Southwestern Medical School, Dallas, Texas 75390 7208, USA
    Clin Dermatol 21:447-54. 2003
    ..The current understanding of NHRs and future directions for NHR ligands in dermatology are discussed...
  72. doi request reprint The use of ustekinumab in autoimmune disease
    Caitriona Ryan
    Baylor Research Institute, Department of Dermatology, 3900 Junius Street, Suite 1125, Dallas, Texas 75204, USA
    Expert Opin Biol Ther 10:587-604. 2010
    ..Ustekinumab is an antibody to the common p40 subunit of IL-12 and IL-23, which has been studied in the treatment of psoriasis, psoriatic arthritis, Crohn's disease and multiple sclerosis...
  73. ncbi request reprint Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Am Acad Dermatol 51:534-42. 2004
    ..Tumor necrosis factor-alpha is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-alpha, blocking its biologic activity...
  74. ncbi request reprint Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    Clin Immunol 111:28-37. 2004
    ..Reduction in lesional, activated T cells induces improvement in psoriatic plaques. Galiximab (IDEC-114), an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation...
  75. ncbi request reprint A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis
    Craig L Leonardi
    St Louis University School of Medicine, St Louis, MO 63117, USA
    Dermatology 213:204-14. 2006
    ..Efalizumab is a recombinant monoclonal immunoglobulin G1 (IgG1) antibody approved for use in psoriasis patients...
  76. ncbi request reprint Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial
    Kenneth B Gordon
    Loyola University Medical Center, Maywood, Ill 60153, USA
    JAMA 290:3073-80. 2003
    ..Because T-cell interactions are involved in the pathophysiology of psoriasis, therapy with a T-cell modulator may have beneficial effects on psoriasis severity and health-related quality of life (HRQL)...
  77. ncbi request reprint Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis
    Frank C Victor
    Clinical Research Center, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Clin Dermatol 21:392-7. 2003
    ..The role of TNF-alpha in the pathogenesis of psoriasis is reviewed, along with clinical trials demonstrating the efficacy of new anti-TNF-alpha immunobiologics in the treatment of psoriasis and psoriatic arthritis...
  78. ncbi request reprint Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks
    Jonathan Weiss
    Gwinnett Clinical Research Center, Snellville, Georgia, USA
    Cutis 70:22-9. 2002
    ..Most patients experienced mild to moderate facial irritation of predictable onset and duration. Once-daily administration of 0.5% fluorouracil cream for 1, 2, or 4 weeks is safe and effective for the treatment of AKs...
  79. ncbi request reprint A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
    Mark Lebwohl
    Departments of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Int J Dermatol 41:269-74. 2002
    ..A clobetasol propionate foam product is as effective as clobetasol propionate solution in the treatment of scalp psoriasis...
  80. ncbi request reprint Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial
    Craig L Leonardi
    Saint Louis University School of Medicine, St Louis, Missouri, USA
    J Am Acad Dermatol 52:425-33. 2005
    ..Efalizumab inhibits multiple T-cell-mediated processes...
  81. doi request reprint Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial
    Alexa B Kimball
    Clinical Unit for Research Trials in Skin CURTIS, Massachusetts General and Brigham and Women s Hospitals, Harvard Medical School, 50 Staniford St, No 246, Boston, MA 02114, USA
    Arch Dermatol 144:200-7. 2008
    ..To investigate the efficacy and safety of ABT-874, an interleukin 12/23 monoclonal antibody, in psoriasis...
  82. doi request reprint Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD 20814, USA
    Dermatology 216:260-70. 2008
    ..However, the association between HRQOL outcomes and more substantial degrees of Psoriasis Area and Severity Index (PASI) response and physician and patient global ratings remains ill defined...
  83. ncbi request reprint Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    Int J Dermatol 45:605-14. 2006
    ..To provide safety data for efalizumab, a recombinant humanized monoclonal IgG(1) antibody, in adults with chronic plaque psoriasis...
  84. ncbi request reprint Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Bethesda, MD 20814, USA
    J Dermatolog Treat 18:341-50. 2007
    ..The effect of adalimumab on patient-reported outcomes (PROs) was evaluated in patients with moderate to severe psoriasis during the initial 16-week, double-blind period of a 52-week, Phase III, multicenter trial...
  85. ncbi request reprint A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads
    Helen Torok
    Trillium Creek Dermatology, Inc, Medina, OH 44526, USA
    J Drugs Dermatol 4:592-7. 2005
    ..Once daily application of TC cream applied intermittently over a long period is a safe, tolerable, and effective treatment for moderate to severe melasma of the face...
  86. ncbi request reprint Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy
    Nick J Lowe
    Clinical Research Specialists, Santa Monica, California, USA
    Int J Dermatol 42:224-30. 2003
    ..This open-label study evaluated the safety and tolerability, efficacy, and pharmacodynamics of repeat courses of alefacept in men and women with chronic plaque psoriasis. This article reports the interim results of this ongoing study...
  87. ncbi request reprint Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array
    Xianghong Zhou
    Department of Biostatistics, Harvard University, Boston 02115, USA
    Physiol Genomics 13:69-78. 2003
    ....
  88. ncbi request reprint Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility
    Rebecca A Speckman
    Departments of Genetics, Washington University School of Medicine, St Louis, MO 63110, USA
    Hum Genet 112:34-41. 2003
    ..The second was a three-locus haplotype lying within the first intron of CMRF35A2 ( TREM5) (TDT P=0.04). The novel markers described here will facilitate additional linkage and association studies between the CMRF35 family and disease...
  89. pmc A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci
    Ying Liu
    Division of Human Genetics, Department of Genetics, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS Genet 4:e1000041. 2008
    ..This region harbors the interleukin 2 (IL2) and interleukin 21 (IL21) genes and was recently shown to be associated with four autoimmune diseases (Celiac disease, Type 1 diabetes, Grave's disease and Rheumatoid Arthritis)...
  90. ncbi request reprint Psoriasis and the metabolic syndrome
    Alice B Gottlieb
    Tufts Medical Center, Boston, MA 02111 1533, USA
    J Drugs Dermatol 7:563-72. 2008
    ..This article reviews the association of psoriasis with metabolic syndrome, as well as the impact of biologic agents that are currently used to treat psoriasis (ie, TNF antagonists) on risk factors for metabolic syndrome...
  91. ncbi request reprint Efficacy and safety of a new triple-combination agent for the treatment of facial melasma
    Susan C Taylor
    Dermatology Associates, St Luke s Roosevelt Hospital, New York, New York 10025, USA
    Cutis 72:67-72. 2003
    ..The most common adverse reactions seen with all treatment groups were erythema, skin peeling, burning, and/or stinging sensation. The majority of treatment-related adverse events were of mild severity...
  92. ncbi request reprint AAD consensus statement on psoriasis therapies
    Jeffrey P Callen
    J Am Acad Dermatol 49:897-9. 2003
  93. ncbi request reprint A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis
    Cynthia Helms
    Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Nat Genet 35:349-56. 2003
    ..This is the second example of loss of a RUNX1 binding site associated with susceptibility to an autoimmune disease. It also suggests defective regulation of SLC9A3R1 or NAT9 by RUNX1 as a susceptibility factor for psoriasis...
  94. ncbi request reprint Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study
    Nicholas Lowe
    UCLA School of Medicine, Santa Monica, CA, USA
    J Cosmet Laser Ther 8:121-7. 2006
    ..To compare the efficacy and tolerability of tazarotene plus hydroquinone versus tazarotene alone in the treatment of facial photodamage...
  95. ncbi request reprint Relapse, rebound, and psoriasis adverse events: an advisory group report
    Wayne Carey
    Royal Victoria Hospital, Montreal, Quebec, Canada
    J Am Acad Dermatol 54:S171-81. 2006
    ....
  96. ncbi request reprint Definitions of measures of effect duration for psoriasis treatments
    Kenneth B Gordon
    Arch Dermatol 141:82-4. 2005
  97. ncbi request reprint Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR
    Cynthia Helms
    Department of Genetics, Washington University School of Medicine, Box 8232, 4566 Scott Avenue, St Louis, Missouri, 63110, USA
    Hum Genet 118:466-76. 2005
    ..The introduction of a potential binding site for the RUNX/AML family of transcription factors in intron 7, is also specific to these HLA-C alleles. These variants need to be investigated further for their role as PSORS1...
  98. doi request reprint Rethinking eligibility creep
    Maryanne Kazanis
    J Am Acad Dermatol 59:165-7; author reply 167. 2008